Clinical Research Directory
Browse clinical research sites, groups, and studies.
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
Breast cancer is the most common malignancy in women worldwide. Patients with breast cancer are often diagnosed at later stages and have a strong desire for breast conservation, necessitating neoadjuvant chemotherapy. Tumors of different molecular subtypes and individual variations among patients lead to significant differences in treatment efficacy. Precise assessment of patients' responses to treatment regimens is imperative in advancing prognosis of breast cancer. In this study, 58 patients diagnosed with breast cancer and scheduled for neoadjuvant therapy will be recruited. Patient-derived organoids from their tumor biopsies will be utilized to evaluate the sensitivity of chemotherapy regimen. These drugs primarily include Doxorubicin, Carboplatin, Cyclophosphamide, Paclitaxel, as well as targeted therapies such as Herceptin and Pertuzumab.
Official title: Consistency of Organoids Based Drug Sensitivity and Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
58
Start Date
2023-12-06
Completion Date
2025-12-01
Last Updated
2025-01-07
Healthy Volunteers
No
Interventions
Biopsy
Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
Locations (1)
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, China